Citius Pharmaceuticals (CTXR) vs Tvardi Therapeutics (TVRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Citius Pharmaceuticals (CTXR) has outperformed Tvardi Therapeutics (TVRD) over the past year, losing 62.0% versus a loss of 97.3%. Over five years, CTXR leads with a -99.1% price change compared with -99.8% for TVRD. Tvardi Therapeutics is the larger company by market cap ($14.4 million vs $13.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTXR | TVRD |
|---|---|---|
| Share price | $0.4887 | $1.08 |
| Market cap | $13.42M | $14.41M |
| 1-day change | -2.47% | -1.82% |
| YTD return | -37.10% | -74.88% |
| 1-year return | -61.97% | -97.29% |
| 5-year return | -99.06% | -99.77% |
| EPS (TTM) | $-1.75 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.19 | $43.65 |
| 52-week low | $0.469 | $0.93 |
| Distance from 52-week high | -77.68% | -97.53% |
| Analyst consensus | none | buy |
| Avg. price target upside | +718.50% | +756.48% |
| Average volume | 527.79K | 424.45K |
| Shares outstanding | 27.45M | 13.34M |
| Employees | 23 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTXR has outperformed TVRD by 35.3 percentage points over the past year.
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Healthcare · Biotechnology · 23 employees
About Tvardi Therapeutics
TVRD stock →Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Healthcare · Biotechnology · 12 employees
CTXR vs TVRD FAQ
Which is bigger, Citius Pharmaceuticals or Tvardi Therapeutics?
Tvardi Therapeutics (TVRD) is larger, with a market capitalization of $14.41M compared with $13.42M for Citius Pharmaceuticals (CTXR).
Which stock has performed better over the past year, CTXR or TVRD?
CTXR returned -61.97% over the past 12 months, compared with -97.29% for TVRD (price return, excluding dividends). Past performance does not predict future results.
Are Citius Pharmaceuticals and Tvardi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.